Related Experiment Video
Updated: Feb 20, 2026

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation
Published on: June 17, 2015
Utility of reproductive life plans in identification of potentially teratogenic medication use: A pilot study
Natalie DiPietro Mager1, Caitlin Mills2, April Snelling3,4
1Pharmacy Practice, Ohio Northern University Raabe College of Pharmacy, Ada, OH, USA.
Background:
Teratogenic medications increase risks of miscarriage, fetal death, and/or birth defects. It is important to identify whether women of childbearing potential are taking these medications and to minimize exposure to these agents through change in drug therapy before conception and/or use of effective contraception to prevent conception.
Objective:
To determine the utility of reproductive life plans as tools to identify women using potentially teratogenic medications.
Methods:
A retrospective review was conducted on reproductive life plans completed by women receiving services as part of the Toledo-Lucas County Healthy Start program. The medication section of the reproductive life plan was reviewed to determine: if it was completed; categories of medications reported (prescription, over-the-counter, vitamin/herbal); potentially teratogenic medications listed; contraception use and method.
Results:
Medication lists were completed for 437 of the 580 reproductive life plans reviewed (75%). Thirty-five women (8%) reported use of a potentially teratogenic medication; most commonly reported agents included blood pressure medications and antidepressants. Only 10 women taking a potentially teratogenic medication (29%) reported using some form of contraception, half of which reported use of a less effective method such as condoms.
Conclusion:
The reproductive life plan can be a useful tool to identify women of childbearing age who require intervention due to use of potentially teratogenic medications. Efforts are needed to ensure complete and accurate reporting of medication use in reproductive life plans, and to promote effective contraceptive use among women taking potentially teratogenic medications.
More Related Videos
05:45Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
Published on: October 10, 2025
06:11Author Spotlight: Exploring the Long-Term Health Impacts of Intracytoplasmic Sperm Injection on Offspring
Published on: May 17, 2024
Related Concept Videos
Teratogenicity
Pharmacokinetics in Pediatric Patients: Drug Excretion
Toxicity Testing in Animals
Factors Affecting Drug Response: Overview
Drug Toxicity: Risk factors
Mutagenicity and Carcinogenicity